CDKL5 Deficiency Disorder
New CDKL5 deficiency disorder research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), small open-label data linked purified cannabidiol to early seizure drops that were less consistent by 12 months, while EEG and daily-life measures continued to develop. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Cannabidiol over time. Attention moved from early response to how long benefits last.
- Sleep and illness patterns. Reports described real-world symptom patterns beyond baseline seizures.
- EEG tracking. EEG work shifted from severity correlation to timing details in development.
- Measuring daily life. Measurement studies clarified what can show change, and what may not.
- Preclinical therapies. Several lab and mouse approaches were reported, but not tested in people.
New
September 2026
- EEG background changes. EEG background activity became more abnormal over the first two years.
- Spasm age window. Epileptic spasms were most common in late infancy.
- EEG and development scores. Some EEG features were linked with lower developmental scores.
- Neuron transport changes. Mouse and lab studies linked CDKL5 loss to slower transport inside neurons.
August 2026
- Resting EEG patterns. Resting EEG patterns lined up with CDD symptom severity.
- Sound and vision EEG. EEG responses to sounds and sights did not track severity.
- Seizures during fever. Many families reported fewer seizures during febrile illness.
- Missing daily-life issues. Some surveys miss sleep, digestion, safety, and caregiver burden.
July 2026
- Edited cell model. Researchers made lab cells with the CDKL5 p.Lys58Met change.
- Lower CDKL5 output. These cells had less CDKL5 RNA message and protein.
- Cell health signals. These cells survived less and showed more cell-death signals.
June 2026
- Early brain supports. In mice, CDKL5 loss shifted when brain support structures formed.
- Regional brain timing. Nearby visual areas showed different timing changes over development.
- Early MRI overlap. In one infant, early MRI findings resembled another disorder.
May 2026
- Blood vesicle protein signals. In a small study, proteins measured in blood vesicle samples differed between people with CDD and neurotypical controls, suggesting possible research tracking signals.
- Links to severity scores. In the same dataset, some blood proteins rose or fell alongside higher clinical severity scores.
- Ganaxolone cell pathway effects. In lab enzyme and cell experiments, ganaxolone was linked to changes in PTP1B and TRKB/BDNF-related signaling, including effects in CDKL5 knockout cells.
- Mouse brain connectivity differences. Brain imaging in a CDD mouse model suggested wiring changes in specific regions and circuits rather than a single whole-brain shift.
April 2026
- Gene editing in cells. Researchers restored CDKL5 expression using gene editing in patient-derived cells, not in people.
- Lab neuron readouts. After editing, the cells showed improvement on neuron-related laboratory measurements.
- CDKL5 phosphorylation changes. In cell studies, CDKL5 phosphorylation (a chemical control tag) shifted during lab-driven neuron-like changes.
March 2026
- 2-AG signal changes biology. In a CDKL5 mouse model, increasing the natural brain signal 2-AG changed brain signaling measures, without broad changes in the behaviors tested.
- Jumping decreased at higher dose. At a higher dose, stereotypic jumping decreased in the mouse study.
- Microglia responses varied by dose. Microglia (immune-like brain cells) showed different responses at different doses, suggesting more than one effect may be involved.
- CDKL5 forms cell clusters. In cell experiments, CDKL5 was reported to form droplet-like clusters, and this clustering was linked to a readout of CDKL5 enzyme activity.
February 2026
- Cannabidiol durability. In a small group, purified cannabidiol was linked to strong early seizure reduction, but seizure control was less consistent by 12 months.
- Lab and mouse therapies. Studies in cells and mice tested CDKL5 delivery methods and a KCC2-targeting approach, but these results remain exploratory because they were not studied in people.
- Clinical course in a small cohort. A small hospital cohort reported seizure onset around 6 months with substantial developmental challenges, and some behaviors were reported more often in females than males.
January 2026
- Motor test floor effect. One motor scale often could not detect change in CDD.
- Types of sleep problems. Sleep problems varied, including insomnia, night waking, and sleepiness.
- Sleep and other symptoms. Sleep problems were reported more often with seizures and constipation.
Get the monthly update by email
Subscribe here to receive an email when a new monthly CDKL5 deficiency disorder update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).